Follow the people · Insider
Karen L. Zaderej
Karen L. Zaderej files insider transactions with the SEC as a director of EyePoint (EYPT). We hold 1 disclosed purchase or sale filed since 21 December 2011, 1 of them in the last 90 days.
- Files forEYPT
- Disclosed buys and sells1 in all, 1 in the last 90 days
- Last disclosure18 August 2026
Positions held
3 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 11 July 2022 — 18 August 2026Director · EyePoint (EYPT)20 Form 4 lines · source: SEC Form 4
- Filed 19 December 2011 — 21 March 2024CEO · Axogen (AXGN)132 Form 4 lines · source: SEC Form 4
- Filed 13 September 2018 — 26 November 2019Director · Viveve Medical (VIVE)7 Form 4 lines · source: SEC Form 4
Everything they disclosed
120 entries, newest first — one per disclosure report, one per Form 4 line- ▲ bought on the open market 10,600 shares of EyePointSEC Form 418 August 2026Common Stock · traded 18 August 2026 · filed 18 August 2026
- was granted 40,000 shares of EyePoint (a derivative holding)SEC Form 46 January 2026Stock Option (Right to Buy) · traded 2 January 2026 · filed 6 January 2026
- was granted 40,000 shares of EyePoint (a derivative holding)SEC Form 46 January 2026Stock Option (Right to Buy) · traded 2 January 2026 · filed 6 January 2026
- exercised options over 2,000 shares of EyePoint Pharmaceuticals (a derivative holding)SEC Form 411 July 2025Restricted Stock Units · traded 11 July 2025 · filed 11 July 2025
- exercised options over 2,000 shares of EyePoint PharmaceuticalsSEC Form 411 July 2025Common Stock · traded 11 July 2025 · filed 11 July 2025
- ▲ bought on the open market 5,000 shares of EyePoint PharmaceuticalsSEC Form 419 May 2025Common Stock · traded 16 May 2025 · filed 19 May 2025
- ▲ bought on the open market 5,000 shares of EyePoint PharmaceuticalsSEC Form 419 May 2025Common Stock · traded 19 May 2025 · filed 19 May 2025
- ▲ bought on the open market 5,000 shares of EyePoint PharmaceuticalsSEC Form 415 May 2025Common Stock · traded 14 May 2025 · filed 15 May 2025
- ▲ bought on the open market 5,000 shares of EyePoint PharmaceuticalsSEC Form 415 May 2025Common Stock · traded 15 May 2025 · filed 15 May 2025
- was granted 40,000 shares of EyePoint Pharmaceuticals (a derivative holding)SEC Form 47 January 2025Stock Option (Right to Buy) · traded 3 January 2025 · filed 7 January 2025
- ▲ bought on the open market 12,500 shares of EyePoint PharmaceuticalsSEC Form 421 August 2024Common Stock · traded 19 August 2024 · filed 21 August 2024
- exercised options over 2,000 shares of EyePoint Pharmaceuticals (a derivative holding)SEC Form 412 July 2024Restricted Stock Units · traded 11 July 2024 · filed 12 July 2024
- exercised options over 2,000 shares of EyePoint PharmaceuticalsSEC Form 412 July 2024Common Stock · traded 11 July 2024 · filed 12 July 2024
- exercised options over 84,847 shares of Axogen (a derivative holding)SEC Form 425 March 2024Restricted Stock Units · traded 16 March 2024 · filed 25 March 2024
- exercised options over 12,500 shares of Axogen (a derivative holding)SEC Form 425 March 2024Restricted Stock Units · traded 16 March 2024 · filed 25 March 2024
- exercised options over 12,975 shares of Axogen (a derivative holding)SEC Form 425 March 2024Restricted Stock Units · traded 16 March 2024 · filed 25 March 2024
- exercised options over 84,847 shares of AxogenSEC Form 425 March 2024Common Stock · traded 16 March 2024 · filed 25 March 2024
- ▼ sold on the open market 33,028 shares of AxogenSEC Form 425 March 2024Common Stock · traded 21 March 2024 · filed 25 March 2024
- exercised options over 12,500 shares of AxogenSEC Form 425 March 2024Common Stock · traded 16 March 2024 · filed 25 March 2024
- ▼ sold on the open market 3,086 shares of AxogenSEC Form 425 March 2024Common Stock · traded 21 March 2024 · filed 25 March 2024
- exercised options over 12,975 shares of AxogenSEC Form 425 March 2024Common Stock · traded 16 March 2024 · filed 25 March 2024
- ▼ sold on the open market 3,166 shares of AxogenSEC Form 425 March 2024Common Stock · traded 21 March 2024 · filed 25 March 2024
- was granted 25,014 shares of EyePoint Pharmaceuticals (a derivative holding)SEC Form 49 January 2024Stock Option (Right to Buy) · traded 5 January 2024 · filed 9 January 2024
- was granted 22,076 shares of AxogenSEC Form 413 October 2023Common Stock · traded 18 July 2023 · filed 13 October 2023
- exercised options over 2,000 shares of EyePoint Pharmaceuticals (a derivative holding)SEC Form 412 July 2023Restricted Stock Units · traded 11 July 2023 · filed 12 July 2023
- exercised options over 2,000 shares of EyePoint PharmaceuticalsSEC Form 412 July 2023Common Stock · traded 11 July 2023 · filed 12 July 2023
- was granted 26,100 shares of EyePoint Pharmaceuticals (a derivative holding)SEC Form 422 June 2023Stock Option (Right to Buy) · traded 20 June 2023 · filed 22 June 2023
- was granted 13,000 shares of EyePoint Pharmaceuticals (a derivative holding)SEC Form 422 June 2023Stock Option (Right to Buy) · traded 20 June 2023 · filed 22 June 2023
- exercised options over 25,000 shares of Axogen (a derivative holding)SEC Form 420 March 2023Restricted Stock Units · traded 16 March 2023 · filed 20 March 2023
- exercised options over 12,975 shares of Axogen (a derivative holding)SEC Form 420 March 2023Restricted Stock Units · traded 16 March 2023 · filed 20 March 2023
- was granted 179,000 shares of Axogen (a derivative holding)SEC Form 420 March 2023Employee Stock Option (right to purchase) · traded 16 March 2023 · filed 20 March 2023
- was granted 112,000 shares of Axogen (a derivative holding)SEC Form 420 March 2023Restricted Stock Units · traded 16 March 2023 · filed 20 March 2023
- exercised options over 25,000 shares of AxogenSEC Form 420 March 2023Common Stock · traded 16 March 2023 · filed 20 March 2023
- exercised options over 12,975 shares of AxogenSEC Form 420 March 2023Common Stock · traded 16 March 2023 · filed 20 March 2023
- exercised options over 4,400 shares of Axogen (a derivative holding)SEC Form 429 December 2022Restricted Stock Units · traded 27 December 2022 · filed 29 December 2022
- exercised options over 4,400 shares of AxogenSEC Form 429 December 2022Common Stock · traded 27 December 2022 · filed 29 December 2022
- exercised options over 26,746 shares of Axogen (a derivative holding)SEC Form 416 December 2022Employee Stock Option (right to buy) · traded 15 December 2022 · filed 16 December 2022
- exercised options over 26,746 shares of AxogenSEC Form 416 December 2022Common Stock · traded 15 December 2022 · filed 16 December 2022
- was granted 22,076 shares of AxogenSEC Form 420 July 2022Common Stock · traded 18 July 2022 · filed 20 July 2022
- returned to the issuer 9,081 shares of AxogenSEC Form 420 July 2022Common Stock · traded 19 July 2022 · filed 20 July 2022
- was granted 6,000 shares of EyePoint Pharmaceuticals (a derivative holding)SEC Form 413 July 2022Restricted Stock Units · traded 11 July 2022 · filed 13 July 2022
- was granted 22,000 shares of EyePoint Pharmaceuticals (a derivative holding)SEC Form 413 July 2022Stock Option (Right to Buy) · traded 11 July 2022 · filed 13 July 2022
- exercised options over 25,950 shares of Axogen (a derivative holding)SEC Form 418 March 2022Restricted Stock Units · traded 16 March 2022 · filed 18 March 2022
- was granted 169,694 shares of Axogen (a derivative holding)SEC Form 418 March 2022Restricted Stock Units · traded 16 March 2022 · filed 18 March 2022
- was granted 317,185 shares of Axogen (a derivative holding)SEC Form 418 March 2022Employee Stock Option (right to purchase) · traded 16 March 2022 · filed 18 March 2022
- exercised options over 25,950 shares of AxogenSEC Form 418 March 2022Common Stock · traded 16 March 2022 · filed 18 March 2022
- was granted 13,978 shares of AxogenSEC Form 417 February 2022Common Stock · traded 15 February 2022 · filed 17 February 2022
- exercised options over 4,400 shares of Axogen (a derivative holding)SEC Form 429 December 2021Restricted Stock Units · traded 27 December 2021 · filed 29 December 2021
- exercised options over 4,400 shares of AxogenSEC Form 429 December 2021Common Stock · traded 27 December 2021 · filed 29 December 2021
- had shares withheld for tax on 1,752 shares of AxogenSEC Form 429 December 2021Common Stock · traded 27 December 2021 · filed 29 December 2021
- exercised options over 3,125 shares of Axogen (a derivative holding)SEC Form 422 December 2021Restricted Stock Units · traded 20 December 2021 · filed 22 December 2021
- exercised options over 3,125 shares of AxogenSEC Form 422 December 2021Common Stock · traded 20 December 2021 · filed 22 December 2021
- had shares withheld for tax on 1,243 shares of AxogenSEC Form 422 December 2021Common Stock · traded 20 December 2021 · filed 22 December 2021
- exercised options over 52,375 shares of Axogen (a derivative holding)SEC Form 429 November 2021Employee Stock Option (right to purchase) · traded 24 November 2021 · filed 29 November 2021
- exercised options over 52,375 shares of AxogenSEC Form 429 November 2021Common Stock · traded 24 November 2021 · filed 29 November 2021
- exercised options over 8,254 shares of AxogenSEC Form 416 August 2021Common Stock · traded 12 August 2021 · filed 16 August 2021
- exercised options over 46,500 shares of AxogenSEC Form 416 August 2021Common Stock · traded 13 August 2021 · filed 16 August 2021
- exercised options over 8,254 shares of Axogen (a derivative holding)SEC Form 416 August 2021Employee Stock Option (right to buy) · traded 12 August 2021 · filed 16 August 2021
- exercised options over 46,500 shares of Axogen (a derivative holding)SEC Form 416 August 2021Employee Stock Option (right to buy) · traded 13 August 2021 · filed 16 August 2021
- exercised options over 75,000 shares of AxogenSEC Form 410 August 2021Common Stock · traded 10 August 2021 · filed 10 August 2021
- ▼ sold on the open market 14,756 shares of AxogenSEC Form 410 August 2021Common Stock · traded 6 August 2021 · filed 10 August 2021
- ▼ sold on the open market 1,259 shares of AxogenSEC Form 410 August 2021Common Stock · traded 6 August 2021 · filed 10 August 2021
- ▼ sold on the open market 22,902 shares of AxogenSEC Form 410 August 2021Common Stock · traded 6 August 2021 · filed 10 August 2021
- ▼ sold on the open market 2,083 shares of AxogenSEC Form 410 August 2021Common Stock · traded 6 August 2021 · filed 10 August 2021
- exercised options over 75,000 shares of Axogen (a derivative holding)SEC Form 410 August 2021Employee Stock Option (right to purchase) · traded 10 August 2021 · filed 10 August 2021
- was granted 22,077 shares of AxogenSEC Form 421 July 2021Common Stock · traded 19 July 2021 · filed 21 July 2021
- had shares withheld for tax on 8,812 shares of AxogenSEC Form 421 July 2021Common Stock · traded 20 July 2021 · filed 21 July 2021
- exercised options over 100,000 shares of Axogen (a derivative holding)SEC Form 420 April 2021Employee Stock Option (right to purchase) · traded 16 April 2021 · filed 20 April 2021
- exercised options over 100,000 shares of AxogenSEC Form 420 April 2021Common Stock · traded 16 April 2021 · filed 20 April 2021
- exercised options over 34,500 shares of AxogenSEC Form 429 March 2021Common Stock · traded 25 March 2021 · filed 29 March 2021
- exercised options over 19,000 shares of Axogen (a derivative holding)SEC Form 429 March 2021Employee Stock Option (right to buy) · traded 25 March 2021 · filed 29 March 2021
- exercised options over 15,500 shares of Axogen (a derivative holding)SEC Form 429 March 2021Employee Stock Option (right to buy) · traded 25 March 2021 · filed 29 March 2021
- was granted 76,600 shares of Axogen (a derivative holding)SEC Form 418 March 2021Employee Stock Option (right to purchase) · traded 16 March 2021 · filed 18 March 2021
- was granted 50,000 shares of Axogen (a derivative holding)SEC Form 418 March 2021Restricted Stock Units · traded 16 March 2021 · filed 18 March 2021
- was granted 16,021 shares of AxogenSEC Form 418 February 2021Common Stock · traded 16 February 2021 · filed 18 February 2021
- had shares withheld for tax on 4,182 shares of AxogenSEC Form 418 February 2021Common Stock · traded 17 February 2021 · filed 18 February 2021
- was granted 13,978 shares of AxogenSEC Form 418 February 2021Common Stock · traded 16 February 2021 · filed 18 February 2021
- had shares withheld for tax on 3,504 shares of AxogenSEC Form 418 February 2021Common Stock · traded 17 February 2021 · filed 18 February 2021
- ▼ sold on the open market 65,000 shares of AxogenSEC Form 412 January 2021Common Stock · traded 8 January 2021 · filed 12 January 2021
- was granted 8,800 shares of AxogenSEC Form 430 December 2020Common Stock · traded 27 December 2020 · filed 30 December 2020
- ▼ sold on the open market 3,500 shares of AxogenSEC Form 430 December 2020Common Stock · traded 29 December 2020 · filed 30 December 2020
- exercised options over 19,375 shares of Axogen (a derivative holding)SEC Form 428 December 2020Employee Stock Option (right to buy) · traded 23 December 2020 · filed 28 December 2020
- exercised options over 19,375 shares of AxogenSEC Form 428 December 2020Common Stock · traded 23 December 2020 · filed 28 December 2020
- was granted 3,125 shares of AxogenSEC Form 422 December 2020Common Stock · traded 18 December 2020 · filed 22 December 2020
- ▼ sold on the open market 1,275 shares of AxogenSEC Form 422 December 2020Common Stock · traded 21 December 2020 · filed 22 December 2020
- ▼ sold on the open market 14,000 shares of AxogenSEC Form 410 November 2020Common Stock · traded 9 November 2020 · filed 10 November 2020
- exercised options over 11,625 shares of AxogenSEC Form 420 April 2020Common Stock · traded 16 April 2020 · filed 20 April 2020
- exercised options over 11,625 shares of Axogen (a derivative holding)SEC Form 420 April 2020Employee Stock Option (right to buy) · traded 16 April 2020 · filed 20 April 2020
- was granted 80,200 shares of Axogen (a derivative holding)SEC Form 418 March 2020Employee Stock Option (right to purchase) · traded 16 March 2020 · filed 18 March 2020
- was granted 51,900 shares of Axogen (a derivative holding)SEC Form 418 March 2020Restricted Stock Units · traded 16 March 2020 · filed 18 March 2020
- was granted 13,978 shares of AxogenSEC Form 420 February 2020Common Stock · traded 18 February 2020 · filed 20 February 2020
- had shares withheld for tax on 5,429 shares of AxogenSEC Form 420 February 2020Common Stock · traded 18 February 2020 · filed 20 February 2020
- was granted 16,015 shares of AxogenSEC Form 420 February 2020Common Stock · traded 18 February 2020 · filed 20 February 2020
- was granted 40,000 shares of AxogenSEC Form 417 January 2020Common Stock · traded 1 January 2020 · filed 17 January 2020
- returned to the issuer 10,112 shares of AxogenSEC Form 417 January 2020Common Stock · traded 1 January 2020 · filed 17 January 2020
- was granted 6,250 shares of AxogenSEC Form 420 December 2019Common Stock · traded 18 December 2019 · filed 20 December 2019
- was granted 330,000 shares of Viveve Medical (a derivative holding)SEC Form 427 November 2019Non-Qualified Stock Option (Right to Buy) · traded 26 November 2019 · filed 27 November 2019
- ▲ bought on the open market 75,000 shares of AxogenSEC Form 412 August 2019Common Stock · traded 9 August 2019 · filed 12 August 2019
- was granted 37,829 shares of Viveve MedicalSEC Form 42 July 2019Common Stock · traded 1 July 2019 · filed 2 July 2019
- exercised options over 18,056 shares of Axogen (a derivative holding)SEC Form 431 May 2019Employee Stock Option (right to buy) · traded 29 May 2019 · filed 31 May 2019
- exercised options over 18,056 shares of AxogenSEC Form 431 May 2019Common Stock · traded 29 May 2019 · filed 31 May 2019
- was granted 35,000 shares of Viveve Medical (a derivative holding)SEC Form 431 May 2019Non-Qualified Stock Option (Right to Purchase) · traded 29 May 2019 · filed 31 May 2019
- was granted 14,248 shares of Viveve MedicalSEC Form 43 April 2019Common Stock · traded 1 April 2019 · filed 3 April 2019
- was granted 16,015 shares of AxoGenSEC Form 419 February 2019Common Stock · traded 15 February 2019 · filed 19 February 2019
- was granted 9,524 shares of Viveve MedicalSEC Form 42 January 2019Common Stock · traded 31 December 2018 · filed 2 January 2019
- was granted 59,700 shares of AxoGen (a derivative holding)SEC Form 431 December 2018Employee Stock Option (right to purchase) · traded 27 December 2018 · filed 31 December 2018
- was granted 17,600 shares of AxoGen (a derivative holding)SEC Form 431 December 2018Restricted Stock Units · traded 27 December 2018 · filed 31 December 2018
- exercised options over 30,000 shares of AxoGenSEC Form 421 December 2018Common Stock · traded 19 November 2018 · filed 21 December 2018
- exercised options over 30,000 shares of AxoGen (a derivative holding)SEC Form 421 December 2018Employee Stock Option (right to purchase) · traded 19 December 2018 · filed 21 December 2018
- exercised options over 70,000 shares of AxoGenSEC Form 421 November 2018Common Stock · traded 19 November 2018 · filed 21 November 2018
- had shares withheld for tax on 6,761 shares of AxoGenSEC Form 421 November 2018Common Stock · traded 19 November 2018 · filed 21 November 2018
- exercised options over 70,000 shares of AxoGen (a derivative holding)SEC Form 421 November 2018Employee Stock Option (right to purchase) · traded 19 November 2018 · filed 21 November 2018
- ▼ sold on the open market 13,000 shares of AxoGenSEC Form 415 November 2018Common Stock · traded 13 November 2018 · filed 15 November 2018
- ▼ sold on the open market 12,000 shares of AxoGenSEC Form 415 November 2018Common Stock · traded 14 November 2018 · filed 15 November 2018
- was granted 746 shares of Viveve MedicalSEC Form 44 October 2018Common Stock · traded 1 October 2018 · filed 4 October 2018
- was granted 70,000 shares of Viveve Medical (a derivative holding)SEC Form 414 September 2018Non-Qualified Stock Options · traded 13 September 2018 · filed 14 September 2018
- had shares withheld for tax on 10,060 shares of AxoGenSEC Form 49 August 2018Common Stock · traded 7 August 2018 · filed 9 August 2018
- exercised options over 175,000 shares of AxoGenSEC Form 46 August 2018Common Stock · traded 2 August 2018 · filed 6 August 2018
- exercised options over 175,000 shares of AxoGen (a derivative holding)SEC Form 46 August 2018Stock Option (right to purchase) · traded 2 August 2018 · filed 6 August 2018
- was granted 75,000 shares of AxoGen (a derivative holding)SEC Form 420 December 2017Employee Stock Option (right to purchase) · traded 18 December 2017 · filed 20 December 2017
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.